Integrating Pharmacoproteomics into Early-Phase Clinical Development: State-of-the-Art, Challenges, and Recommendations

Integrating Pharmacoproteomics into Early-Phase Clinical Development: State-of-the-Art, Challenges, and Recommendations

Pharmacoproteomics is the study of disease-modifying and toxicity parameters associated with therapeutic drug administration, using analysis of quantitative and temporal changes to specific, predetermined, and select proteins, or to the proteome as a whole. Pharmacoproteomics is a rapidly evolving f...

Full description

Bibliographic Details
Main Authors: Savita Nandal, Tal Burt
Format: Article
Language:English
Published: MDPI AG 2017-02-01
Series:International Journal of Molecular Sciences
Subjects:
proteome
proteomics
drug development
early phase development
clinical development
biomarker
Omics
clinical research
phase 0
phase 1
phase 2
proof-of-concept
proof-of-mechanism
proof-of-principle
first-in-human (FIH) studies
pharmacogenomics
pharmacometabolomics
pharmacokinetics (PK)
pharmacodynamics (PD)
drug toxicity
Online Access:http://www.mdpi.com/1422-0067/18/2/448

Internet

http://www.mdpi.com/1422-0067/18/2/448

Similar Items